pH-Regulated Release Technology for Diverse Industries
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts the core technology of the original patent, which controls the release of active pharmaceutical ingredients, to various non-pharmaceutical industries, including agriculture, environmental monitoring, wastewater treatment, and food preservation.
Background and Problem Solved
The original patent addressed the issue of opioid abuse by developing a self-regulated release system for pharmaceutical compositions. However, this technology has broader applications beyond the pharmaceutical industry. The new inventive concept solves the problem of inefficient nutrient release in livestock feeding, suboptimal crop yields, ineffective environmental pollutant detection, inadequate wastewater treatment, and shortened food shelf life.
Detailed Description of the Inventive Concept
The inventive concept involves applying the pH-modifying and buffering principles to diverse industries. In agriculture, pH-modifying feed additives regulate nutrient release and absorption, preventing over-ingestion and adverse health effects in livestock. In environmental monitoring, pH-sensitive sensors and buffering agents detect and neutralize pollutants. In wastewater treatment, pH-modifying agents control contaminant release and absorption, enhancing treatment efficacy. In food preservation, pH-dependent solubility coatings extend shelf life by regulating release and absorption of preservatives.
Novelty and Inventive Step
The new inventive concept is novel and non-obvious because it applies the original patent's pH-regulated release technology to entirely new industries and use cases, which were not previously considered. The inventive step lies in recognizing the broader applicability of the technology and adapting it to solve distinct problems in various fields.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different pH-modifying agents, adapting the technology for use in other industries such as cosmetics or biotechnology, or integrating the pH-regulated release system with other technologies, such as nanotechnology or biodegradable materials.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the agriculture, environmental monitoring, wastewater treatment, and food preservation industries, offering solutions to pressing problems and opportunities for companies to differentiate themselves and gain a competitive advantage.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/02 |
| A | A61 | A61K9/2009 |
| A | A61 | A61K9/2027 |
| A | A61 | A61K9/2077 |
| A | A61 | A61K31/5517 |
| A | A61 | A61K47/32 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and controlled release technologies, with expertise in drug delivery systems, pH-dependent solubility mechanisms, and compositional modifications for regulated ingredient release across multiple technical domains
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degree in pharmaceutical sciences, chemical engineering, or materials science, possessing knowledge of drug delivery mechanisms, buffer systems, and cross-industry application of controlled release technologies
Obviousness Rationale
A PHOSITA would recognize the fundamental principle of pH-dependent release mechanism disclosed in the source patent as broadly applicable beyond pharmaceutical contexts. The core technological concept of using buffering ingredients to modulate ingredient release is fundamentally transferable across different technical domains. The PTD's variations represent predictable extensions of the original patent's core technological principle by applying known controlled release strategies to alternative industrial applications.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,629 |
|---|---|
| Title | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| Assignee(s) | Acurx Pharmaceuticals, Inc. |